Summary

Overview
Global palmar hyperhidrosis treatment market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.
Palmar hyperhidrosis also known as sweaty palms, is a medical condition in which a person sweats excessively and unpredictably from their hands. People with palmar hyperhidrosis may sweat even when the temperature is cool or when they are at rest. It mainly evolves from a localized hyperactivity of the sympathetic autonomic system and it can be triggered by stressful events. Sweaty palms are the result of the overactivation of eccrine sweat glands.
Moreover, the treatment of palmar hyperhidrosis includes antiperspirants such as aluminum zirconium trichloro hydrate and aluminum chloride hexahydrate mainly act on the opening of the sweat glands blocking the elimination of sweat, iontophoresis by the process of sending gentle electrical current through water to shut down the sweat glands temporarily, anticholinergic drugs are used to display antiperspirant efficacy by blocking the effect of acetylcholine on postsynaptic muscarinic receptors, preventing sweat gland activation, botox is effective in relieving the symptoms of palmar hyperhidrosis and in severe cases with excessing hand sweating, Endoscopic Thoracic Sympathectomy (ETS) is the most appropriate cure for palmar hyperhidrosis.
Market Dynamics: Drivers
Increasing adoption of iontophoresis devices
The increasing adoption of iontophoresis devices is expected to drive the market over the forecast period. Iontophoresis offers a non-invasive procedure that involves passing a mild electric current through the skin's surface, temporarily blocking the sweat glands. This non-surgical approach may appeal to individuals seeking less invasive treatments thus increasing the adoption for palmar hyperhidrosis treatment.
For instance, on October 7, 2022, Dermadry launched a revamped range of its best-selling iontophoresis device to treat excessive sweating (hyperhidrosis) of the hands, feet, and underarms. This device has been reimagined for a seamless, comfortable, and effortless treatment experience suited for the millions of people affected by hyperhidrosis globally.
Moreover, iontophoresis has been shown to be effective in reducing excessive sweating. Positive outcomes and patient satisfaction may contribute to increased adoption. For instance, the International Hyperhidrosis Society organization study found that iontophoresis helped 91% of patients with excessive palmoplantar (hands and feet) sweating. Another study showed that iontophoresis reduced palmoplantar sweating by 81%.
According to the study, during iontophoresis, a medical device is used to pass a mild electrical current through water (usually using shallow pans for hands or feet or specific pads for other body areas) and through the skin's surface. There are no significant or serious side effects and the benefits are long-term.
In Addition, some iontophoresis devices are designed for home use, allowing individuals to manage their palmar hyperhidrosis without frequent visits to healthcare facilities. The convenience of home use can drive adoption. Compared to surgical interventions, iontophoresis typically has minimal side effects, making it a favorable option for those concerned about potential risks associated with more invasive procedures.
Further, the increasing prevalence of palmar hyperhidrosis, rising FDA approvals, increasing clinical trials, increasing demand for novel therapeutics, increasing awareness and technological advancements are the factors expected to drive the market over the forecast period.
Restraints
Factors such as complications and adverse effects associated with the treatment drugs, the high cost of the treatment, availability of alternative treatment options, lack of awareness about the treatments available, and limited efficacy of some treatment options are expected to hamper the market.
Segment Analysis
The global palmar hyperhidrosis treatment market is segmented based on disease type, treatment type, sales channel and region.
The anticholinergic drugs segment accounted for approximately 48.3% of the palmar hyperhidrosis treatment market share
The anticholinergic drugs segment is expected to hold the largest market share over the forecast period. Usually, sweating is controlled by the sympathetic nervous system, which releases the neurotransmitter acetylcholine to stimulate sweat gland activity. Anticholinergic drugs block the action of acetylcholine, reducing the stimulation of sweat glands. Anticholinergic drugs can have a systemic effect on the entire body, affecting sweat glands in various areas, including the palms. This makes them suitable for treating palmar hyperhidrosis.
For instance, on March 27, 2023, Hisamitsu Pharmaceutical Co., Inc. released that it had obtained approval for manufacturing and marketing of APOHIDE Lotion 20%, for the primary palmar hyperhidrosis treatment drug (generic name: oxybutynin hydrochloride) in Japan. Oxybutynin hydrochloride is a type of anticholinergic used is most commonly used for palmar hyperhidrosis.
Further, many anticholinergic drugs are administered orally and topiccally, providing a convenient and systemic approach to reducing sweating. This is particularly beneficial for individuals with widespread hyperhidrosis. Compared to surgical interventions, anticholinergic drugs offer a non-invasive treatment option. This can be appealing to individuals who prefer oral medications over more invasive procedures. In addition, their wide adoption also increases the demand for the anticholinergic drugs.
Geographical Analysis
North America accounted for approximately 39.7% of the market share
North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and advanced healthcare facilities. North America especially the United States is known for its strong presence of major players such as pharmaceutical companies, biotechnology companies and medical device companies. The presence of major players actively performs the clinical trials to develop more accurate therapeutics for better patient outcomes.
For instance, on April 29, 2023, Aquavit Holdings, a biotechnology company focused on the development of botulinum toxin applications, received FDA clearance to initiate clinical trials for DTX-024, following its submission of Investigational New Drug Applications. Aquavit will begin its Phase III trials for DTX-024 (aqubotulinumtoxinA with intradermal microinjector) under the study protocol titled S.W.E.A.T. II (Safety with Efficacy of AQUATOX for palmar hyperhidrosis Trial).
Furthermore, the region is also known for its advanced healthcare infrastructure, including advanced medical facilities, specialized clinics, academic and research institutes and access to a wide range of treatment options. This facilitates the treatment of palmar hyperhidrosis by using advanced and appropriate therapeutics. As the research activities increase, the therapeutics are developed more precisely by reducing the adverse effects and complications associated with the therapeutics, which results in better patient outcomes.
Competitive Landscape
The major global players in the palmar hyperhidrosis treatment market include Allergan plc, Thermo Fisher Scientific Inc., Journey Medical Corporation, Revance Therapeutics, Inc., AdvaCare Pharma, C Cube Advanced Technologies, Avanor Healthcare Ltd, Midas Pharma GmbH, Galderma SA and Indetouch Exporters Enterprise among others.
COVID-19 Impact Analysis
The COVID-19 pandemic significantly impacted the global palmar hyperhidrosis treatment market. During the pandemic, patients are hesitant to seek medical attention for palmar hyperhidrosis due to concerns about exposure to the virus. This led to a decline in the number of patients seeking treatment for palmar hyperhidrosis. The pandemic also created unprecedented challenges to the market by temporarily disrupting many clinical trials and research activities due to the redirected focus on the COVID-19 pandemic. The pandemic also disrupted the supply chain of these treatment drugs globally.
Market Segmentation
By Disease Type
• Primary Focal Hyperhidrosis
• Secondary Generalized Hyperhidrosis
By Treatment Type
• Antiperspirants
o Aluminum Zirconium Trichlorohydrate
o Aluminum Chloride Hexahydrate
o Others
• Iontophoresis
• Anticholinergic Drugs
o Oxybutynin Hydrochloride
o Glycopyrrolate
o Benztropine
o Propantheline
o Others
• Botulinum Toxin (Botox)
• Endoscopic Thoracic Sympathectomy (ETS)
• Others
By Sales Channel
• Distribution Channel
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• End-User
o Hospitals
o Specialty Clinics
o Dermatology Clinics
o Academic And Research Institutes
o Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Why Purchase the Report?
• To visualize the global palmar hyperhidrosis treatment market segmentation based on disease type, treatment type, sales channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of palmar hyperhidrosis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global palmar hyperhidrosis treatment market report would provide approximately 61 tables, 58 figures, and 189 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents